1GSK, PFE : GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In...
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
ViiV announces new study data showing zero HIV cases with Apretude
GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi (SGIOY) as ...
ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...
Le Lézard17h
Lytho Recognized in G2's 2025 Best Software Awards for Project Management Excellence
Lytho, a leading provider of creative workflow solutions, is proud to announce its inclusion in G2's 2025 Best ...
ViiV Healthcare announces data from EMBRACE Phase IIb study
ViiV Healthcare, majority owned by GSK (GSK), with Pfizer (PFE) (PE) and Shionogi as shareholders, announced findings from the company’s ...
ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.1 The ...
Fierce Biotech17h
GSK posts data on HIV assets vying for roles in 6-month combo
GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...